Multicenter Trial of Single-Dose Azithromycin vs. Ceftriaxone in the Treatment of Uncomplicated Gonorrhea
The DOI matches its Crossref record.
Abstract
BACKGROUND AND OBJECTIVES: Azithromycin is a new, long-acting azalide antibiotic that is active against Neisseria gonorrhoeae. A single oral dose of 1.0 g is effective against uncomplicated genital infection with Chlamydia trachomatis. GOAL OF THIS STUDY: To compare the efficacy and tolerance of single-dose treatment of uncomplicated gonorrhea with azithromycin, 2.0 g orally, and ceftriaxone, 250 mg intramuscularly. STUDY DESIGN: Seven hundred twenty-four men and women with presumptive, uncomplicated gonorrhea were treated with azithromycin 2.0 g orally or ceftriaxone 250 mg intramuscularly in a 2:1 ratio in a multicenter, open, randomized control trial in 10 public sexually transmitted disease clinics in the United States. Patients were followed up in 5 to 9 days and, for a subset of patients, 12 to 18 days after treatment. The main outcome measures were the isolation of N. gonorrhoeae and C. trachomatis and patient-reported side effects. RESULTS: Among infected patients who returned for follow-up, N. gonorrhoeae was eradicated from all anatomic sites in 370 of 374 (98.9%; 95% confidence interval [95%CI] 97.9%-100%) treated with azithromycin and 171 of 175 (97.7%; 95%CI 95.5%-99.9%) given ceftriaxone. Treatment with either drug was effective in all 73 patients infected with beta-lactamase-producing N. gonorrhoeae. Chlamydial infection was eradicated in all 17 patients given azithromycin who returned and were recultured at follow-up and in two of seven patients given ceftriaxone (P < 0.001). Gastrointestinal side effects occurred in 35.3% (95%CI 30.7%-39.8%) of patients given azithromycin; of those with symptoms, these were moderate in 10.1% and severe in 2.9%. CONCLUSIONS: Azithromycin 2.0 g and ceftriaxone 250 mg are equally effective in the treatment of uncomplicated gonorrhea. Azithromycin was associated with a relatively high frequency of gastrointestinal side effects and is expensive, but it has the advantages of oral administration and efficacy against concomitant chlamydial infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
Unemo, M., & Shafer, W. M. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-14 · Cited by 1,151
2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
Bignell, C., Unemo, M., The European STI Guidelines Editorial Board, Radcliffe, K., Jensen, J. S., Babayan, K., Barton, S., Cusini, M., Gomberg, M., Janier, M., et al. (2013) · International Journal of STD & AIDS · doi:10.1177/0956462412472837 · Cited by 483
Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.
Riedner, G., Rusizoka, M., Todd, J., Maboko, L., Hoelscher, M., Mmbando, D., Samky, E., Lyamuya, E., Mabey, D., Grosskurth, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044284 · Cited by 296
The Macrolides: Erythromycin, Clarithromycin, and Azithromycin
Alvarez-Elcoro, S., & Enzler, M. J. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.6.613 · Cited by 282
UK national guideline for the management of gonorrhoea in adults, 2011
Bignell, C., FitzGerald, M., & (Guideline Development Group) (2011) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.011267 · Cited by 270
Metadata
- Authors
- HANDSFIELD, H. H., DALU, Z. A., MARTIN, D. H., DOUGLAS, J. M., MCCARTY, J. M., SCHLOSSBERG, D., & STUDY GROUP, A. G.
- Venue
- Sexually Transmitted Diseases
- Published
- 1994-03
- Volume
- 21
- Issue
- 2
- Pages
- 107-111
- ISSN
- 0148-5717 (ISSN-L)
- OpenAlex
- W2013981975
- Cited by
- 146
- References
- 0
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multicenter Trial of Single-Dose Azithromycin vs. Ceftriaxone in the Treatment of Uncomplicated Gonorrhea. https://app.cochat.ai/papers/10.1097/00007435-199403000-00010
- The paper
- HANDSFIELD, H. H., DALU, Z. A., MARTIN, D. H., DOUGLAS, J. M., MCCARTY, J. M., SCHLOSSBERG, D., & STUDY GROUP, A. G. (1994). Multicenter Trial of Single-Dose Azithromycin vs. Ceftriaxone in the Treatment of Uncomplicated Gonorrhea. Sexually Transmitted Diseases. https://doi.org/10.1097/00007435-199403000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.